(Reuters) - Submission of the New Drug Application could be delayed until the first quarter of next year as the U.S. Food and Drug Administration has asked the company to include assessment of whether the drug could cause cancer, Somaxon said.
The company, which was in talks with marketing partners for Silenor, had earlier expected to file the application in the third quarter of this year.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment